ReShape Lifesciences Inc. - FORM 8-K - EX-99.1 - EXHIBIT 99.1 - May 10, 2018

Attached files

file filename
8-K - 8-K - ReShape Lifesciences Inc.oblnq1-18earnings8xk.htm



Obalon Announces First Quarter 2018 Financial Results
SAN DIEGO, CA May 10, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its unaudited financial results as of and for the first quarter ended March 31, 2018.
First Quarter 2018 highlights:
•
Highest number of treating accounts ever, up 40% vs Q4-17 and 300% vs Q1-17
•
Highest number of patients treated ever, up over 60% vs Q4-17 and 240% vs Q1-17
•
Highest unique website visits ever, up over 70% vs Q4-17 and over 260% vs Q1-17
•
Highest Find-A-Doctor searches ever, up 55% vs Q4-17 and over 600% vs Q1-17
•
Todd Wood joins as new Vice President of Global Sales
The Company reported revenue of $1.3 million for the first quarter of 2018, compared to $1.5 million for the first quarter of 2017. Net loss was reported at $12.1 million compared to a net loss of $7.7 million in the first quarter of 2017 and net loss per share for the quarter was $0.71 as compared to net loss per share of $0.47 in the first quarter of 2017.
Cost of revenue was $0.8 million during the three months ended March 31, 2018, in-line with $0.8 million for the prior year period. Gross profit for the first quarter of 2018 was $0.6 million, resulting in a gross margin of 43%, compared to a gross profit of $0.6 million and gross margin of 44% for the first quarter of 2017.
Research and Development expense for the first quarter of 2018 totaled $2.6 million, up from $2.4 million in the first quarter of 2017, and Selling, General and Administrative expense increased to $10.0 million for the first quarter of 2018, compared to $5.9 million in the first quarter 2017. Selling, General and Administrative expenses in the first quarter 2018 included approximately $1.3 million related to investigation of the whistleblower allegations and terminated equity offering.
Operating loss for the first quarter of 2018 was $12.1 million, compared to an operating loss of $7.7 million for the first quarter of 2017.
As of March 31, 2018, cash and cash equivalents were $33.5 million and debt was $10.0 million.

1


“In Q1-18, we continued the second half of our New Year’s Resolution Promotion strategy with an increased focus on driving utilization at the account level,” said Bill Plovanic, CFO. “Although first quarter revenues were slower than Q4-17, we were very pleased with the underlying metrics as we strive to build a sustainable business. New patient starts, the number of accounts treating, unique website visits and Find-A-Doctor searches grew meaningfully and were the highest level ever.”
Call Information
A conference call to discuss first quarter 2018 financial results is scheduled for today, May 10, 2018, at 5:00 PM Eastern Time (2:00 PM Pacific Time). Interested parties may access the conference call by dialing (844) 889-7791 (U.S.) or (661) 378-9934 (international) using passcode 3693617.  Media and individuals will be in a listen-only mode. Participants are asked to dial in a few minutes prior to the call to register for the event.  The conference call will also be webcast live at: https://edge.media-server.com/m6/p/q4jkh9dx.
An archive of the webcast will be available for twelve months following the event on the Obalon Therapeutics, Inc. website located at http://investor.obalon.com in the “News & Events” section. 
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
For Obalon Therapeutics, Inc.
Investor Contact:
William Plovanic
Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103
wplovanic@obalon.com
Media:
Megan Driscoll
EvolveMKD

2


Office Phone: +1 646 517 4220
mdriscoll@evolvemkd.com




OBALON THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except shares and per share data)

 
Three Months Ended March 31,
 
2018
 
2017
 
(Unaudited)
Revenue
$
1,346

 
$
1,472

Cost of revenue
769

 
823

Gross profit
577

 
649

Operating expenses:
 
 
 

Research and development
2,639

 
2,400

Selling, general and administrative
10,006

 
5,940

Total operating expenses
12,645

 
8,340

Loss from operations
(12,068
)
 
(7,691
)
Interest expense, net
(37
)
 
(54
)
Other expense
(21
)
 
—

      Net loss
(12,126
)
 
(7,745
)
Other comprehensive income (loss)
6

 
(18
)
Net loss and comprehensive loss
$
(12,120
)
 
$
(7,763
)
Net loss per share, basic and diluted
$
(0.71
)
 
$
(0.47
)
Weighted-average common shares outstanding, basic and diluted
16,986,656

 
16,562,030



















3



OBALON THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except shares and par value data)
 
March 31, 2018
 
December 31, 2017
Assets
(Unaudited)
 
 

Current assets:
 

 
 

Cash and cash equivalents
$
33,478

 
$
21,108

Short-term investments
—

 
23,292

Accounts receivable, net of allowance of $621 and $239, respectively
2,553

 
4,223

Inventory
1,867

 
1,418

Other current assets
1,187

 
1,714

Total current assets
39,085

 
51,755

Property and equipment, net
1,422

 
1,346

Total assets
$
40,507

 
$
53,101

Liabilities and Stockholders’ Equity
 

 
 

Current liabilities:
 

 
 

Accounts payable
$
2,304

 
$
1,276

Accrued compensation
1,831

 
4,494

Deferred revenue
337

 
510

Other current liabilities
1,677

 
1,773

Current portion of long-term loan
2,961

 
1,958

Total current liabilities
9,110

 
10,011

     Deferred rent
—

 
13

     Long-term loan, excluding current portion
6,973

 
7,964

Total long-term liabilities
6,973

 
7,977

Total liabilities
16,083

 
17,988

Commitments and contingencies
 
 
 
Stockholders’ equity:
 

 
 

   Common stock, $0.001 par value; 300,000,000 shares authorized as of March 31, 2018 and December 31, 2017; 17,596,282 and 17,500,604 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively
18

 
18

Additional paid-in capital
147,905

 
146,474

Accumulated other comprehensive gain (loss)
1

 
(5
)
Accumulated deficit
(123,500
)
 
(111,374
)
Total stockholders’ equity
24,424

 
35,113

Total liabilities and stockholders’ equity
$
40,507

 
$
53,101
















4


OBALON THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
 
Three Months Ended March 31,
 
2018
 
2017
 
(Unaudited)
Operating activities:
 

 
 

Net loss
$
(12,126
)
 
$
(7,745
)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 

Depreciation and amortization
129

 
66

Stock-based compensation
1,389

 
463

Loss on disposal of fixed assets
107

 
—

(Accretion) amortization of investment (discount) premium, net
(5
)
 
3

Amortization of debt discount
11

 
10

Change in operating assets and liabilities:
 
 
 

Accounts receivable, net
1,670

 
(1,035
)
Accounts receivable from related party
—

 
515

Inventory
(449
)
 
(101
)
Other current assets
527

 
240

Accounts payable
1,074

 
217

Accrued compensation
(2,663
)
 
(942
)
Deferred revenue
(173
)
 
50

Other current and long term liabilities
(93
)
 
(94
)
Net cash used in operating activities
(10,602
)
 
(8,353
)
Investing activities:
 

 
 

Purchases of short-term investments
—

 
(25,029
)
Maturities of short-term investments
23,302

 
2,500

Purchase of property and equipment
(358
)
 
(381
)
Net cash provided by (used in) investing activities
22,944

 
(22,910
)
Financing activities:
 

 
 

Proceeds from sale of common stock upon exercise of stock options
28

 
—

Net cash provided by financing activities
28

 
—

Net increase (decrease) in cash and cash equivalents
12,370

 
(31,263
)
Cash and cash equivalents at beginning of period
21,108

 
72,975

Cash and cash equivalents at end of period
$
33,478

 
$
41,712

Supplemental cash flow information:
 

 
 

Interest paid
$
149

 
$
130

Property and equipment in accounts payable
$
46

 
$
129



5

ReShape Lifesciences Inc. Reports